Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Related Concept Videos

The Retinoblastoma Gene01:20

The Retinoblastoma Gene

4.2K
Tumor suppressor genes are normal genes that can slow down cell division, repair DNA mistakes, or program the cells for apoptosis in case of irreparable damage. Hence, they play an essential role in preventing the proliferation of damaged cells.
The first-ever tumor suppressor gene called Rb was identified in retinoblastoma - a rare eye tumor in children. In inherited forms of the disease, a child inherits one defective copy of the Rb gene, which predisposes them to retinoblastoma. However,...
4.2K

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by
Same authorSame journal

An Abnormal Clone with a der(12;22)(q10;q10) as a Rare Abnormality Within the Context of dup(1)(q25q43), Deletion of ABL1 and a t(8;21) in a Pediatric Male Patient with Acute Myeloid Leukemia.

Journal of the Association of Genetic Technologists·2026
Same author

Complex Chromothripsis-like Features in Plasma Cell Myeloma: A Case Report and Review of the Literature.

Diagnostics (Basel, Switzerland)·2026
Same author

Clinical Knowledge Representation in Data Science.

Annual review of biomedical data science·2026
Same author

A Rare Case of De Novo Acute Myeloid Leukemia, Featuring a <i>KMT2A</i> (<i>MLL</i>) Amplification.

Diagnostics (Basel, Switzerland)·2026
Same author

Epigenetics in B-CLL.

International journal of genomics·2026
Same author

Violence Exposure, Mental Health, Cognitive Functioning, and Disabilities in Incarcerated Youth.

Research square·2026

Related Experiment Video

Updated: Aug 29, 2025

A Chromatin Immunoprecipitation Assay to Identify Novel NFAT2 Target Genes in Chronic Lymphocytic Leukemia
09:52

A Chromatin Immunoprecipitation Assay to Identify Novel NFAT2 Target Genes in Chronic Lymphocytic Leukemia

Published on: December 4, 2018

7.6K

CRLF2 Gene in B-cell Acute Lymphoblastic Leukemia.

Wendy Su1,2, Alair Zhao1,2, Jonah Nahoul1,2

  • 1University of California Los Angeles, Los Angeles, CA.

Journal of the Association of Genetic Technologists
|September 7, 2022
PubMed
Summary
This summary is machine-generated.

CRLF2 deregulation in B-cell acute lymphoblastic leukemia (B-ALL) is linked to poor prognosis and specific genetic alterations. Research explores its pathways, clinical impact, and targeted therapies like blinatumomab for B-ALL treatment.

More Related Videos

Investigation of the Transcriptional Role of a RUNX1 Intronic Silencer by CRISPR/Cas9 Ribonucleoprotein in Acute Myeloid Leukemia Cells
09:16

Investigation of the Transcriptional Role of a RUNX1 Intronic Silencer by CRISPR/Cas9 Ribonucleoprotein in Acute Myeloid Leukemia Cells

Published on: September 1, 2019

7.7K
Immunoglobulin Gene Sequence Analysis In Chronic Lymphocytic Leukemia: From Patient Material To Sequence Interpretation
09:02

Immunoglobulin Gene Sequence Analysis In Chronic Lymphocytic Leukemia: From Patient Material To Sequence Interpretation

Published on: November 26, 2018

21.4K

Related Experiment Videos

Last Updated: Aug 29, 2025

A Chromatin Immunoprecipitation Assay to Identify Novel NFAT2 Target Genes in Chronic Lymphocytic Leukemia
09:52

A Chromatin Immunoprecipitation Assay to Identify Novel NFAT2 Target Genes in Chronic Lymphocytic Leukemia

Published on: December 4, 2018

7.6K
Investigation of the Transcriptional Role of a RUNX1 Intronic Silencer by CRISPR/Cas9 Ribonucleoprotein in Acute Myeloid Leukemia Cells
09:16

Investigation of the Transcriptional Role of a RUNX1 Intronic Silencer by CRISPR/Cas9 Ribonucleoprotein in Acute Myeloid Leukemia Cells

Published on: September 1, 2019

7.7K
Immunoglobulin Gene Sequence Analysis In Chronic Lymphocytic Leukemia: From Patient Material To Sequence Interpretation
09:02

Immunoglobulin Gene Sequence Analysis In Chronic Lymphocytic Leukemia: From Patient Material To Sequence Interpretation

Published on: November 26, 2018

21.4K

Area of Science:

  • Hematology
  • Oncology
  • Genetics

Background:

  • B-cell acute lymphoblastic leukemia (B-ALL) accounts for 75% of ALL cases, often involving chromosomal abnormalities.
  • CRLF2 expression deregulation occurs in 5-15% of B-ALL patients, frequently associated with Ph-like B-ALL.
  • CRLF2 alterations, including translocations and mutations, are linked to a poor prognosis in B-ALL.

Purpose of the Study:

  • To review the role of CRLF2 in B-ALL.
  • To summarize CRLF2's molecular pathways, clinical significance, and incidence.
  • To discuss current and future therapeutic strategies for CRLF2-driven B-ALL.

Main Methods:

  • Literature review of studies on CRLF2 in B-ALL.
  • Analysis of molecular mechanisms, genetic alterations, and prognostic implications.
  • Summary of therapeutic approaches, including immunotherapy and clinical trials.

Main Results:

  • CRLF2 deregulation is a significant factor in a subset of B-ALL, particularly Ph-like B-ALL.
  • Specific genetic events like IGH translocations and CRLF2 mutations drive poor outcomes.
  • Immunotherapy such as blinatumomab shows promise, with ongoing trials for CRLF2 B-ALL.

Conclusions:

  • CRLF2 alterations represent a critical area of focus in B-ALL pathogenesis and treatment.
  • Understanding CRLF2's role is essential for developing effective targeted therapies.
  • Further research is needed to optimize treatment strategies for patients with CRLF2-altered B-ALL.